Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 12, 373 (2006)
Published online: 29 March 2006 | doi:10.1038/nm0406-373b
US drug approval ignores science's subtleties, experts say
Emily Waltz1
- New York
Abstract
The FDA should be more flexible in reacting to safety concerns.
A multiple sclerosis drug yanked off the market last year is on track to return, prompting some experts to say it should perhaps not have been withdrawn in the first place.A US Food and Drug Administration (FDA) advisory panel in March voted unanimously to allow the drug, Tysabri, back on the market with some restrictions.
To read this story in full you will need to login or make a payment (see right).
